Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
ImmunoGen, Inc.

ImmunoGen, Inc. (IMGN) Stock Overview

Explore ImmunoGen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IMGN●NASDAQ
HealthcareBiotechnology
$31.23
$0.005(0.02%)
U.S. Market is Open · 15:27

ImmunoGen, Inc. (IMGN)

Meyka AI Score

Z

Key Financials

Market Cap8.7B
P/E Ratio-35.54
EPS (TTM)$-0.28
ROE-0.93%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$61.31

IMGN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of ImmunoGen, Inc. (NASDAQ: IMGN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, ImmunoGen, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IMGN on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $61.31 for the NASDAQ listing.

Key metrics behind ImmunoGen, Inc.'s NASDAQ-traded stock include a P/E ratio of -35.54 and a market capitalization of 8.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of IMGN on the NASDAQ.

Price Performance (NASDAQ: IMGN)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
0.02%
3-Month Change
6.93%
6-Month Change
98.95%
Year-to-Date (YTD) Change
5.31%
1-Year Change
726.32%
3-Year Change
250.96%
5-Year Change
1083.14%
All-Time (Max) Change
228.79%

Contact Information

https://www.abbvie.com/immunogen.html
781 895 0600
830 Winter Street, Waltham, MA, 02451-1477

Company Facts

2,770 Employees
IPO DateNov 17, 1989
CountryUS

Frequently Asked Questions